Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H27NO4S.ClH |
| Molecular Weight | 401.948 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.C[S@@+]([O-])CC[C@](CO)(C(=O)O[C@H]1CN2CCC1CC2)C3=CC=CC=C3
InChI
InChIKey=QHXPHLKFVDPMLS-XPTPVYCOSA-N
InChI=1S/C19H27NO4S.ClH/c1-25(23)12-9-19(14-21,16-5-3-2-4-6-16)18(22)24-17-13-20-10-7-15(17)8-11-20;/h2-6,15,17,21H,7-14H2,1H3;1H/t17-,19+,25+;/m0./s1
Revatropate is a muscarinic antagonist with selectivity for M1 and M3 receptor subtypes. Significant improvement in airway function was shown in horses with heaves after inhalation of revatropate, and it was found to be a safe and effective bronchodilator. Early clinical studies in chronic obstructive airway disease (COAD) patients also showed that inhaled revatropate was an effective bronchodilator, and well tolerated.
Originator
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
586346-96-5
Created by
admin on Tue Apr 01 17:03:50 GMT 2025 , Edited by admin on Tue Apr 01 17:03:50 GMT 2025
|
PRIMARY | |||
|
69110544
Created by
admin on Tue Apr 01 17:03:50 GMT 2025 , Edited by admin on Tue Apr 01 17:03:50 GMT 2025
|
PRIMARY | |||
|
BJ9G601BQR
Created by
admin on Tue Apr 01 17:03:50 GMT 2025 , Edited by admin on Tue Apr 01 17:03:50 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
